Rongchang Bio (09995): Taetaesip (trade name: Taiai) achieved the primary endpoint in Phase A of the China Phase III clinical study for the treatment of IgA nephropathy.

Zhtng Finance and Economics APP News, Rongchang Biotech (09995) announced that the company's independently developed global first BLyS/APRIL dual-target fusion protein innovative drug Tepesib (trade name: Thai Love) used to treat IgA nephropathy (IgAN) in China reached the main research endpoint of Phase III clinical research. The Group will soon submit a Biologics License Application (BLA) to the China National Medical Products Administration (NMPA) Drug Evaluation Center (CDE).